TITLE

Causal relationships between gut microbiome and age-related traits.

Authors

Federica Grosso[1], Daniela Zanetti[1], Serena Sanna[1]

Affiliations

[1]Institute for Genetic and Biomedical Research (IRGB) of the National Research Council (CNR), Monserrato (CA), Italy

Corresponding author:

Serena Sanna

Institute for Genetic and Biomedical Research (IRGB) of the National Research Council (CNR), Cittadella Universitaria di Monserrato, SS555 Km 4500, Monserrato (CA), Italy

Email: serena.sanna@cnr.it

Tel: +39 0706754593

Abstract

In the past 20 years, the involvement of gut microbiome in human health has received particular attention, but its contribution to age-related diseases remains unclear. To address this, we performed a comprehensive investigation of 4,033 potential causal relationships between 37 traits representing gut microbiome composition and function and 109 age-related phenotypes, using two-samples Mendelian randomization. Five causal relationships remained significant after multiple testing correction and sensitivity analyses, specifically between two taxa of *Coriobacteriales* and the risk of developing age-related macular degeneration, species *Bifidobacterium adolescentis* and levels of TNFSF12 protein in plasma, and the lactose-galactose degradation microbial I pathway and levels of IL-15Rα and TRAIL proteins in plasma. The causal relationship between the lactose-galactose degradation I pathway and TRAIL protein levels was further confirmed using independent data. These results support the role of gut microbiome in regulating the inflammatory circuit, albeit future studies are needed to investigate the underlying biological mechanisms.

Keywords

causal inference, aging, gut microbiome, inflammatory proteins, age-related macular degeneration, mendelian randomization, longevity, lactose and galactose degradation I pathway, TRAIL

Introduction

Many human disorders, such as cancer, diabetes, neurodegeneration and cardiovascular diseases, are closely linked to the intricate and multifactorial process of aging, which involves physiological changes. To identify possible therapeutic targets for age-related disorders and to understand the mechanism of aging, it is essential to study changes within different body compartments during lifespan, such as those in the gut microbiome [1]. The human gastrointestinal tract (gut) hosts a vast microbial community of approximately 100 trillion microorganisms, which change significantly throughout life. Furthermore, it is composed of a large number of immune cells that constantly communicate with the gut microbiota, an essential process for maintaining immune homeostasis. Disruption of this interaction can lead to dysbiosis, which can contribute to the development of autoimmune diseases, inflammatory diseases, susceptibility to infections and other health problems [2], [3]. Therefore, changes in the gut microbiota influence various aspects of both gut and systemic immune and inflammatory responses, suggesting a link to the age-related decline in immune function, often referred to as immune aging, immunosenescence or inflammaging [3].

During aging significant changes occur in the gut microbiome. For example, opportunistic pathogens such as *Enterobacteria*, which can induce intestinal inflammation, increase, while by contrast beneficial commensals such as *Bacteroides*, *Bifidobacteria* and *Lactobacilli* decrease [3]. These changes in microbial composition underline the importance of studying the microbiota throughout life to better understand its role in aging and associated diseases. However, it remains uncertain whether changes in the microbiota drive immunosenescence or whether the immunosenescence process impacts the microbiota. Given this ambiguity, we investigated the causal relationship between the gut microbiome and age-related diseases, along with associated immune-related circulating proteins.

To investigate potential causal links between the gut microbiome and age-related traits, the Mendelian randomization (MR) technique was employed, thus controlling for confounding factors. Other studies

[4-10] have used MR to assess a causal relationship between gut microbiome and specific age-related
traits. For example, Mao et al. [6] investigated its causality with age-related macular degeneration;
Chen et al. [7], [10] explored links with longevity traits; and Bo et al. [8] focused specifically on
frailty. In our work, we opted for a comprehensive analysis with an extensive number of age-related
outcomes. Furthermore, we emphasized the importance of a rigorous approach to MR analyses. This
involves employing stringent parameters to ensure validity of MR assumptions such as the
independence and strong association of the instrumental variables (IVs), performing multiple testing
correction and sensitivity analysis, and excluding reverse causality bias via bidirectional MR.
Moreover, our study followed the STROBE-MR (Strengthening the Reporting of Observational
Studies in Epidemiology using Mendelian Randomization) checklist [11] and guidelines from
Burgess et al. [12].

Unlike previous studies, we performed replication analyses for the significant results using
independent datasets, a fundamental step that has often been overlooked. Replication [13] is one way
to prevent false positive results from being spread [14], [15]. This approach strengthens the robustness
and reliability of our findings, making them a more solid reference point for understanding the causal
relationships between the gut microbiome and aging-related phenotypes.

Materials and methods

Exposure and outcome selection

A two sample MR was performed to investigate the causal relationship between the gut microbiome
(exposure) and selected age-related phenotypes (outcome). As exposure data we used genome-wide
association study (GWAS) summary statistics collected from a previous study by Lopera-Maya et al.
[16]. Lopera-Maya et al. used shotgun genome sequencing on fecal samples from 7,738 individuals
participating in the Dutch Microbiome Project [17] to derive quantitative information on 207 taxa
and 205 pathways. By analyzing these 412 microbiome variables with GWAS method, they identified
significant genetic associations ($p < 5 \cdot 10^{-8}$) for 37 of these: 18 taxa and 19 pathways; these 37
were considered as exposure for our study. The relevant GWAS summary statistics can be accessed
through the GWAS Catalog (https://www.ebi.ac.uk/gwas/home) [18] **(Supplementary Table 1a)**.

The outcomes of interest are 109 age-related phenotypes including diseases and quantitative traits
(Supplementary Table 1b), of which summarized GWAS results were also collected on GWAS
Catalog [18]. They were selected primarily because of the large sample sizes available for the
respective traits, since sample size is a key factor to increase the statistical power of the analysis. For
inflammatory proteins, on the other hand, instead of selecting proteins from separate GWASs with
the largest sample size, we chose to use all 91 protein GWAS from the study of Zhao et al. [19], which
includes the most comprehensive panel of circulating inflammatory proteins available on GWAS
Catalog **(Supplementary Table 1b)**.

GWAS quality control and selection of instrumental variables

We performed a quality control (QC) screening for each of the downloaded GWAS files (37 for the
microbiome and 109 for the outcomes). In particular, we confirmed that all studies were aligned to
build 37 (genome assembly GRCh37/hg19) or otherwise to a compatible assembly such as hg38

(cardiovascular aging) and assigned missing rsIDs to genetic variants when needed. Furthermore, we
removed variants in the exposure if their effect size was very large and likely unreliable (+/- 4 standard
deviation units).

After QC, we selected genetic variants to be used as IVs for MR analyses. Since MR assumptions
require independent (not in linkage disequilibrium) and highly associated IVs, we selected genome-
wide significant ($p < 5 \cdot 10^{-6}$) independent hits, after linkage disequilibrium clumping using a
window of $10\ Mb$ and R^2 cutoff = 0.001.

To reduce computational time in the clumping process, we used a local version of the European
population (503 samples) genotypes from the 1000 Genomes Project (phase 3) [20], [21], that
excluded variants with minor allele frequency (MAF) less than 1%.

Methods for causal inference

After the general QC of GWAS, two-sample MR analysis was performed, using "TwoSampleMR"
version 0.6.8 package [22], [23] in R environment version 4.4.1. The main MR method we employed
to evaluate causality is the "Inverse Variance Weighted" (IVW) method [24], [25], as it is the strongest
method with the greatest discovery power. To avoid the risk of overestimating the significance of our
findings, we applied a correction for multiple testing within each of the 109 outcomes – the
Benjamini-Hochberg (BH) false discovery rate (FDR) correction [26] – considering a significance
level of 5% after correction.

The MR method relies on three important assumptions: (1) IVs are associated with exposure (relevant
exposure); (2) IVs are not associated with outcome due to confounding pathways (independence); (3)
IVs do not affect the outcome directly, except potentially via exposure (exclusion restriction) [24].

While the first assumption is met by our selection of IV with the clumping method, the other two
assumptions cannot be investigated *a priori*. Therefore, in addition of the IVW method, we employed
other MR methods as sensitivity analyses: weighted median method [27] and MR-PRESSO (using
"MRPRESSO" version 1.0 package on R) [28], [29]. Given the limited power, we considered
significant those tests with nominal p-value less than 0.05 (thus not applying multiple testing
correction). In addition, we specifically investigated the presence of constant horizontal pleiotropy,
heterogeneity, and the influence of a single variant on causal estimates with several statistical tests
[30]. In particular, these included the Egger intercept term which assumes all IVs are affected by the
same amount of pleiotropy, the Cochran's Q statistics which assesses heterogeneity across single IV
causal estimates [31], and the leave-one-out test – where IVW is repeated removing in turn one IV
from the set of IVs. The results were also visualized graphically using scatter plots and leave-one-out
plots.

Significant results after IVW were also subjected to bidirectional MR analysis, it means using the
outcome as exposure and the exposure as outcome, to confirm the lack of significant reverse causal
relationships. This approach ensures that observed associations are not merely due to reverse
causation or confounding, thereby strengthening the validity of causal inferences drawn from the
study.

We then run replication analyses for all significant findings (those passing IVW and sensitivity
analyses), using independent GWAS' datasets as outcome and exposure, if available (**Supplementary
Table 1c**).

Post-hoc power analysis

For all our significant results we calculated the post-hoc power to compare the power of the main and replication analyses and have further information about the strength of our findings. We used for continuous outcomes the formula [32]:

$$Power_C = \Phi\left(\sqrt{(R^2 \beta_c^2 N)} - z_{1-\alpha/2}\right)$$

and for binary outcomes:

$$Power_B = \Phi\left(\sqrt{NR^2\beta_c^2 \frac{ratio}{1+ratio}} - z_{1-\alpha/2}\right)$$

where β_c is the causal effect obtained from main MR analysis, N is the sample size of the outcome's GWAS, R^2 is the exposure's explained variance by the selected IVs and *ratio* is calculated by dividing the number of cases by the number of controls of the outcome GWAS. The function Φ is the cumulative distribution function of the standard normal distribution and $z_{1-\alpha/2}$ is the quantile of the standard normal distribution corresponding $1 - \alpha/2$, for a significance level $\alpha = 0.05$.

To compute the explained variance R^2, required to calculate the statistical power, we used the formula [33]:

$$R^2 = \frac{2\beta^2 MAF(1-MAF)}{2\beta^2 MAF(1-MAF) + 2n\big(se(\beta)\big)^2 MAF(1-MAF)}$$

where MAF is the minor allele frequency, β is the effect size for a given variant and n the sample size of the exposure GWAS. To compute the total proportion of explained variance for each exposure, we summed all R^2 values of all variants included in the IV after harmonization.

Results

Out of the 4,033 MR tests performed, five causal relationships remained significant after multiple-testing correction. The results highlighted a causal link between the gut microbiome and four age-related traits: age-related macular degeneration (AMD) and levels of 3 circulating inflammatory proteins (**Supplementary Table 2**).

Age-related macular degeneration

AMD GWAS was collected from the study of Jiang et al. [34], which analyzed data of 1,295 cases and 455,053 controls from UK Biobank [35]. We found that a genetic predisposition to higher levels of bacteria of the order of *Coriobacteriales* or of family *Coriobacteriaceae* increases the risk of developing AMD disease ($\beta_c = 0.61$, $p_{BH} = 0.047$). All the sensitivity **(Table 1)** and graphical analyses **(Supplementary Figures 2 and 3)** confirmed this result, further supported by the absence of reverse causality (all $p > 0.87$) **(Table 1)**.

We tested the replicability of these causal relationships using three more GWAS data of AMD **(Supplementary Table 1c)**. Albeit the definition of AMD was different, their large sample size provided sufficient power for replication **(Supplementary Figure 5)**. Despite this, none of these three GWASs led to significant results **(Supplementary Figure 4)**.

Inflammatory proteins

The GWAS summary statistics for circulating inflammatory proteins refer to the study of Zhao et al. [19], which analyzed a total of 91 proteins in 11,792 European ancestry individuals **(Supplementary Table 1b)**. Among all the 3,367 MR analyses with the 37 microbiome features, three showed significant MR results after FDR correction. We found that genetic predisposition to an increase in lactose-galactose degradation I (LACTOSECAT) pathway decreases levels of Interleukin-15 receptor subunit alpha measurement (IL-15Rα) ($\beta_c = -0.21$, $p_{BH} = 0.029$) and TNF-related apoptosis-inducing ligand levels (TRAIL or TNFSF10) ($\beta_c = -0.19$, $p_{BH} = 0.006$) proteins in plasma. Furthermore, genetic predisposition to higher levels of the taxon of *Bifidobacterium adolescentis* decreases levels of the tumor necrosis factor ligand superfamily member 12 (TNFSF12 or TWEAK) ($\beta_c = -0.2$, $p_{BH} = 0.0003$) protein in plasma. These results were confirmed by all the sensitivity **(Table 1)** and graphical analyses **(Supplementary Figures 6, 7, 10, 11 and Figures 1a, 1c)** and supported by the absence of reverse causality (all $p > 0.64$) **(Table 1)**.

We then investigated the replicability of these results by using independent GWASs of the outcomes for IL-15Rα and TRAIL. Only the causal relationship between the LACTOSECAT pathway and plasma levels of the TRAIL protein was successfully replicated ($\beta_c = -0.14$, $p = 0.023$) **(Figure 1b, Supplementary Table 2k)**.

In the latter case the platform used to measure the protein was OLINK in both main and replication GWASs. The replication GWAS for IL-15Rα protein, instead, had much lower sample size than the GWAS used in the main analysis and also used a different method to measure proteins. Indeed, they used the SOMAScan method, which has been reported to have low concordance with measurements from the OLINK platform [36].

For TNFSF12 protein we sought to replicate the significant result using both a different exposure's GWAS (from Qin et al. [37]) and outcome's GWAS (from Sun et al. [38]). Of note, in the outcome GWAS the protein was measured using SOMAScan [38]. In both attempts, we were unable to replicate our primary result. When we considered the causal effect identified in the main MR analyses, we detected at least 80% of statistical power in all the replication GWAS datasets tested, apart in the GWASs of IL-15Rα [39], [40] and in the GWAS of TNFSF12 from Sun et al. [38] **(Figure 1d, Supplementary Figures 9** and **13)**.

Further investigation of replicated results

We further investigated the underlying biological meaning of the causal relationship between the LACTOSECAT pathway and TRAIL plasma levels, being this relationship significant and fully replicated. In the study by Lopera-Maya et al. [16] the LACTOSECAT pathway was highly associated to a genetic variant in the *ABO* gene, the gene responsible for determining blood group types **(Supplementary Table 1)**. A recent study by our collaborators [41] has shown that *ABO*-associated species can also utilize N-acetylgalactosamine (GalNAc) sugar from blood type A individuals who can secret the mucosal A-antigen. We therefore aimed to investigate whether the causal relationship observed in our study might be connected to utilization of GalNAc in blood type A individuals.

Specifically, we assessed the causal relationship between the presence of structural variants (SVs) of *Faecalibacterium prausnitzii*, which contain genes that perform GalNAc degradation activity [42], and two outcomes: TRAIL levels and the LACTOSECAT pathway. Of note, this bacteria species was

not detected in Lopera-Maya et al. [16], and thus no GWAS was available for our MR analyses. However, the study of Zhernakova et al. [37] identified human single nucleotide polymorphisms (SNPs) that affect the abundance of the GalNAc utilization gene region, and thus these SNPs could be used to investigate the causal effect of F. *prausnitzii*.

We conducted MR analysis using variable SVs (vSVs) and deletion SVs (dSVs) related to GalNAc activity in *F. prausnitzii* as exposures (**Supplementary Table 1d**), with TRAIL and lactose-galactose degradation I pathway as outcomes. Intriguingly, MR results showed that predisposition to higher load of *F. prausnitzii* SVs (thus higher GalNAc utilization activity) is causally linked with higher levels of the lactose-galactose degradation I pathway, supporting our hypothesis that the activity of this microbial pathway is related to mucosal-A antigen utilization ($p < 0.05$ for all SVs) (**Supplementary Table 2r, 2s**). In contrast, no significant causal relationships were observed with levels of TRAIL protein for any of the tested SVs, therefore we cannot conclude that the link between the LACTOSECAT pathway and the TRAIL protein is related to the utilization of a specific blood type.

Discussion

In this study, we investigated the causal effect of variation in gut microbiome composition and function in modulating age-related traits, using the Mendelian randomization approach. Among all the investigated outcomes, the analyses highlighted a potential causal effect on AMD and 3 inflammatory proteins. A strong and replicable causal relationship highlighted by our study is the one between the lactose-galactose degradation I pathway and the levels of TRAIL protein in plasma. This protein is considered a potential mediator of apoptosis in various biological and pathological contexts, including autoimmunity and infection. Identified in 1996 it is seen as a potential anticancer agent due to its selective induction of apoptosis in tumour cells whilst sparing normal cells [43]. This inflammatory protein is also linked to inflammatory processes within the body that lead to an increased likelihood of age-related diseases, and its role as potential biomarker is being discussed also for cardiovascular diseases [44]. Using statistical analysis, it was not possible to elucidate the biological mechanism underlying the causal link between higher activity of lactose and galactose degradation I pathway and lower level of this inflammatory protein. This pathway activity has been associated to direct metabolization of blood antigens released in the gut from people with A blood type [42]. Individuals with A blood type are also known to have higher risk of developing cardiovascular diseases and cancers [45], [46]. Hence, the negative causal relationship we observed is in line with expectations, since an increase in the activity of the pathway will decrease the levels of TRAIL proteins, which means more inflammation [47]. The influence of the lactose-galactose degradation I pathway on this circulating inflammatory protein is therefore intriguing and warrants further investigation.

There is an extensive growth in literature on the associations between gut microbiome and inflammation, as well as the onset of many chronic and age-related diseases. However, reliability and reproducibility of these findings are limited by several pitfalls in the statistical protocol used, such as a lenient selection of IVs, being limited to one single MR test and not performing sensitivity analyses, and the lack of correction for multiple testing. Furthermore, very few studies have aimed to replicate their findings in independent datasets, leaving their results inconclusive.

Chen et al. [7], [10], for example, investigated the presence of potential causal relationships between gut microbiome and five longevity traits – frailty, health span, lifespan, longevity, parental longevity – using the same GWAS data as our study. Among their exposures there were traits derived from the GWAS carried out on the Dutch Microbiome Project, which we also used in our study. They identified several causal relationships that we were unable to reproduce. The primary differences between their study and ours lie in the methodology, particularly in the threshold used for selecting IVs. Indeed, to avoid overestimating the causal effect, we only focused on microbiome traits with at least one genome-wide significant hit and opted for a more stringent association p-value of $5 \cdot 10^{-6}$, instead of $1 \cdot 10^{-5}$. Furthermore, we did not base our significance on nominal p-values but rather employed multiple testing correction. This approach surely reduces the number of significant findings but strengthens the robustness and reliability of our results. Out of the 168 exposure-outcome significant pairs reported by Chen et al. [7], [10], 12 would survive our pipeline for selection of exposure and only 3 were nominal significant for the IVW test. However, none were significant after adjusting for multiple testing (all p_{BH}>0.16). Additionally, none would pass the sensitivity analyses therefore they would not be considered significant even without applying FDR (**Supplementary Table 3**).

Of note, another study (Mao et al. [6]) has specifically investigated the causal link between gut microbiome and AMD, but the two GWAS used for analyses were different from those used by us. As exposure (microbiome GWASs) they used data from the MiBioGen consortium [41], and as outcome (AMD GWAS) data were derived from FinnGen biobank analysis (round 5), which includes 3,763 cases and 205,359 controls. Using a $p < 1 \cdot 10^{-5}$ as significant threshold to select IV, 6 microbiome features (out of 211 tested) were found to be causally linked to AMD at p < 0.05 (smallest p=0.005). None of these features include species of the order of *Coriobacteriales*. These results, however, were not supported by a correction for multiple testing, therefore they could not be considered statistically significant. In addition, the other MR methods they implemented were not taken into account; for example the pvalues from MR-PRESSO were never significant (all p>0.05). In contrast, the causal relationship we detected with AMD was robust to FDR correction and to all sensitivity analysis we opted for. It must be noted however that despite we have used a stringent and rigorous pipeline, we were unable to replicate the causal relationship using different datasets. One limitation of this replication attempt, however, is that the definition of the AMD disease was not the same in the different GWASs, and thus it would be necessary to repeat these analyses when more extensive data with same definition of the disease will be available.

Our findings highlight the importance of a rigorous methodological approach in the application of MR to study the causal relationships between the gut microbiome and age-related phenotypes. A strict observance to MR guidelines [12], [48] and STROBE-MR [11] is essential to ensure the integrity and reliability of the results and a proper evaluation of finding, concept that extends beyond the specific exposure and outcome we selected. Several findings from previous studies [6], [7], [10] that did not follow the guidelines were in fact not supported by our analyses. Our study also focus attention on the need for replication of the results in independent datasets, rather than assuming that an initial statistical significance can be interpreted as definitive proof of causality. This concept is essential to avoid misinterpretation and to progress towards the discovery of effective therapeutic interventions. The range of applications of MR and related methods for understanding causal mechanisms has in fact expanded rapidly over the past 20 years, coupled with the increasing number of public GWAS studies, and therefore the adherence to a rigorous pipeline is mandatory.

We also acknowledge the study limitations. First, the genetic of microbiome traits has a limited impact on explaining the total variation, therefore only one IV could be selected at $5 \cdot 10^{-8}$ for each trait, significantly impacting power of MR. We mitigated this limitation by using a lower threshold of $5 \cdot 10^{-6}$ to detect more IVs and rigorously assessed the coherence of causal estimates from each IVs using several sensitivity analysis methods. Secondly, we recognize the lack of replication of some results in independent cohorts. Furthermore, we are aware that differences in data collection methods and characteristics of the cohorts analyzed may have introduced sources of bias, which may have prevented the detection of weaker but still relevant relationships.

Conclusion

We investigated the causal relationships between the gut microbiome and age-related phenotypes using the MR approach and ensured the integrity and reliability of the results by a strict adherence to MR guidelines. Our results support a causal role of gut microbiome in age-related macular degeneration and in the regulation of the inflammatory circuit. Particularly robust was the causal link between a microbial pathway for lactose and galactose degradation and levels of the inflammatory protein TRAIL, which was successfully replicated in an independent cohort. While the link is particularly intriguing, we acknowledge that future studies are needed to investigate the underlying biological mechanisms and to further confirm this link, before these insights could be translated into clinical applications for prevention of age-related diseases.

Data availability statement

No data was generated for this study. We used public data, download links are available in **Supplementary Table 1**. The scripts used for all the analyses are publicly available in the GitHub repository: https://github.com/Sanna-s-LAB/Mendelian-randomization-Project.git

Acknowledgements

We thank Daria Zhernakova and Valeria Lo Faro for critical revisions on the manuscript, and Davide Murrau for support and management of our IT infrastructure.

Disclosure statement

None of the authors has conflict of interest to declare.

Funding

This study was supported by project DSB AD006.371 "InvAt" FOE 2022 and project DBA.AD005.225 "NutrAGE" FOE 2021. In addition, we acknowledge Marie-Curie Fellowship to D.Z., acronym 'Sex Dimorphism' (GA n. 101066678) that indirectly made this study possible.

Ethics declaration

For this study only summarized non-individual data was used.

Use of AI statement

We acknowledge the use of artificial intelligence tools, namely ChatGPT 4.0, to improve code efficiency, particularly to reduce the development time of clear and accurate result tables.

References

[1] X. Shen *et al.*, 'Nonlinear dynamics of multi-omics profiles during human aging', *Nat. Aging*, pp. 1–16, Aug. 2024, doi: 10.1038/s43587-024-00692-2.

[2] K. Hou *et al.*, 'Microbiota in health and diseases', *Signal Transduct. Target. Ther.*, vol. 7, no. 1, pp. 1–28, Apr. 2022, doi: 10.1038/s41392-022-00974-4.

[3] R. Nagpal *et al.*, 'Gut microbiome and aging: Physiological and mechanistic insights', *Nutr. Healthy Aging*, vol. 4, no. 4, pp. 267–285, Jun. 2018, doi: 10.3233/NHA-170030.

[4] H. Li and C. Li, 'Causal relationship between gut microbiota and type 2 diabetes: a two-sample Mendelian randomization study', *Front. Microbiol.*, vol. 14, Aug. 2023, doi: 10.3389/fmicb.2023.1184734.

[5] 'Gut microbiome and risk of ischaemic stroke: a comprehensive Mendelian randomization study | European Journal of Preventive Cardiology | Oxford Academic'. Accessed: Jan. 07, 2025. [Online]. Available: https://academic.oup.com/eurjpc/article/30/7/613/7044714

[6] D. Mao *et al.*, 'Causal Effects of Gut Microbiota on Age-Related Macular Degeneration: A Mendelian Randomization Study', *Invest. Ophthalmol. Vis. Sci.*, vol. 64, no. 12, p. 32, Sep. 2023, doi: 10.1167/iovs.64.12.32.

[7] S. Chen, W. Chen, X. Wang, and S. Liu, 'Mendelian randomization analyses support causal relationships between gut microbiome and longevity', *J. Transl. Med.*, vol. 22, no. 1, p. 1032, Nov. 2024, doi: 10.1186/s12967-024-05823-2.

[8] F. Bo *et al.*, 'Exploring the causal relationship between gut microbiota and frailty: a two-sample mendelian randomization analysis', *Front. Med.*, vol. 11, May 2024, doi: 10.3389/fmed.2024.1354037.

[9] A. D. Rosa, 'Causal link between gut microbiota and osteoporosis analyzed via Mendelian randomization', European Review. Accessed: Jan. 07, 2025. [Online]. Available: https://www.europeanreview.org/article/35052

[10] S. Chen *et al.*, 'Consistent signatures in the human gut microbiome of longevous populations', *Gut Microbes*, vol. 16, no. 1, p. 2393756, Dec. 2024, doi: 10.1080/19490976.2024.2393756.

[11] V. W. Skrivankova *et al.*, 'Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement', *JAMA*, vol. 326, no. 16, p. 1614, Oct. 2021, doi: 10.1001/jama.2021.18236.

[12] S. Burgess *et al.*, 'Guidelines for performing Mendelian randomization investigations: update for summer 2023', *Wellcome Open Res.*, vol. 4, p. 186, 2019, doi: 10.12688/wellcomeopenres.15555.3.

[13] Directorate-General for Research and Innovation (European Commission) *et al.*, *Reproducibility of scientific results in the EU: scoping report*. Publications Office of the European Union, 2020. Accessed: Sep. 03, 2024. [Online]. Available: https://data.europa.eu/doi/10.2777/341654

[14] M. R. Munafò *et al.*, 'A manifesto for reproducible science', *Nat. Hum. Behav.*, vol. 1, no. 1, pp. 1–9, Jan. 2017, doi: 10.1038/s41562-016-0021.

[15] M. Baker, '1,500 scientists lift the lid on reproducibility', *Nature*, vol. 533, no. 7604, pp. 452–454, May 2016, doi: 10.1038/533452a.

[16] E. A. Lopera-Maya *et al.*, 'Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project', *Nat. Genet.*, vol. 54, no. 2, pp. 143–151, Feb. 2022, doi: 10.1038/s41588-021-00992-y.

[17] R. Gacesa *et al.*, 'The Dutch Microbiome Project defines factors that shape the healthy gut microbiome', Nov. 27, 2020, *bioRxiv*. doi: 10.1101/2020.11.27.401125.

[18] E. Sollis *et al.*, 'The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource', *Nucleic Acids Res.*, vol. 51, no. D1, pp. D977–D985, Jan. 2023, doi: 10.1093/nar/gkac1010.

[19] J. H. Zhao *et al.*, 'Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets', *Nat. Immunol.*, vol. 24, no. 9, pp. 1540–1551, Sep. 2023, doi: 10.1038/s41590-023-01588-w.

[20] 1000 Genomes, '1000 Genomes | A Deep Catalog of Human Genetic Variation'. Accessed: Jul. 09, 2024. [Online]. Available: https://www.internationalgenome.org/

[21] K. Rogers, '1000 Genomes Project | Genome Mapping & Sequencing', *Encycl. Br.*, Jul. 2024, Accessed: Aug. 26, 2024. [Online]. Available: https://www.britannica.com/event/1000-Genomes-Project

[22] G. Hemani *et al.*, 'The MR-Base platform supports systematic causal inference across the human phenome', *eLife*, vol. 7, p. e34408, May 2018, doi: 10.7554/eLife.34408.

[23] G. Hemani, K. Tilling, and G. D. Smith, 'Orienting the causal relationship between imprecisely measured traits using GWAS summary data', *PLOS Genet.*, vol. 13, no. 11, p. e1007081, Nov. 2017, doi: 10.1371/journal.pgen.1007081.

[24] S. Burgess and S. G. Thompson, *Mendelian Randomization: Methods for Causal Inference Using Genetic Variants*, 2nd ed. Chapman and Hall/CRC, 2021. Accessed: Apr. 11, 2024. [Online]. Available: https://www.mendelianrandomization.com/index.php/book-chapters

[25] S. Burgess, A. Butterworth, and S. G. Thompson, 'Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data', *Genet. Epidemiol.*, vol. 37, no. 7, pp. 658–665, Nov. 2013, doi: 10.1002/gepi.21758.

[26] Benjamini & Hochberg, 'Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing - Benjamini - 1995 - Journal of the Royal Statistical Society: Series B (Methodological) - Wiley Online Library', Journal of the Royal Statistical Society, 1995. Accessed: Jun. 28, 2024. [Online]. Available: https://rss.onlinelibrary.wiley.com/doi/10.1111/j.2517-6161.1995.tb02031.x

[27] J. Bowden, G. Davey Smith, P. C. Haycock, and S. Burgess, 'Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator', *Genet. Epidemiol.*, vol. 40, no. 4, pp. 304–314, May 2016, doi: 10.1002/gepi.21965.

[28] M. Verbanck, C.-Y. Chen, B. Neale, and R. Do, 'Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases', *Nat. Genet.*, vol. 50, no. 5, pp. 693–698, May 2018, doi: 10.1038/s41588-018-0099-7.

[29] R. Do, *Performs the Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) method | https://github.com/rondolab/MR-PRESSO*. (Jun. 15, 2024). R. Accessed: Jul. 01, 2024. [Online]. Available: https://github.com/rondolab/MR-PRESSO

[30] S. Burgess and S. G. Thompson, 'Interpreting findings from Mendelian randomization using the MR-Egger method', *Eur. J. Epidemiol.*, vol. 32, no. 5, pp. 377–389, 2017, doi: 10.1007/s10654-017-0255-x.

[31] N. A. Sheehan and V. Didelez, 'Epidemiology, genetic epidemiology and Mendelian randomisation: more need than ever to attend to detail', *Hum. Genet.*, vol. 139, no. 1, pp. 121–136, Jan. 2020, doi: 10.1007/s00439-019-02027-3.

[32] S. Burgess, 'Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome', *Int. J. Epidemiol.*, vol. 43, no. 3, pp. 922–929, Jun. 2014, doi: 10.1093/ije/dyu005.

[33] J. Yarmolinsky *et al.*, 'Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis', *JNCI J. Natl. Cancer Inst.*, vol. 110, no. 9, pp. 1035–1038, May 2018, doi: 10.1093/jnci/djy081.

[34] L. Jiang, Z. Zheng, H. Fang, and J. Yang, 'A generalized linear mixed model association tool for biobank-scale data', *Nat. Genet.*, vol. 53, no. 11, pp. 1616–1621, Nov. 2021, doi: 10.1038/s41588-021-00954-4.

[35] 'UKBiobank PheWeb'. Accessed: Jul. 04, 2024. [Online]. Available: https://pheweb.org/UKB-Neale/

[36] M. R. Rooney *et al.*, 'Plasma proteomic comparisons change as coverage expands for SomaLogic and Olink', *MedRxiv Prepr. Serv. Health Sci.*, p. 2024.07.11.24310161, Jul. 2024, doi: 10.1101/2024.07.11.24310161.

[37] Y. Qin *et al.*, 'Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort', *Nat. Genet.*, vol. 54, no. 2, pp. 134–142, Feb. 2022, doi: 10.1038/s41588-021-00991-z.

[38] B. B. Sun *et al.*, 'Genomic atlas of the human plasma proteome', *Nature*, vol. 558, no. 7708, pp. 73–79, Jun. 2018, doi: 10.1038/s41586-018-0175-2.

[39] A. Gudjonsson *et al.*, 'A genome-wide association study of serum proteins reveals shared loci with common diseases', *Nat. Commun.*, vol. 13, no. 1, p. 480, Jan. 2022, doi: 10.1038/s41467-021-27850-z.

[40] L. Folkersen *et al.*, 'Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals', *Nat. Metab.*, vol. 2, no. 10, pp. 1135–1148, Oct. 2020, doi: 10.1038/s42255-020-00287-2.

[41] A. Kurilshikov *et al.*, 'Large-scale association analyses identify host factors influencing human gut microbiome composition', *Nat. Genet.*, vol. 53, no. 2, pp. 156–165, Feb. 2021, doi: 10.1038/s41588-020-00763-1.

[42] D. V. Zhernakova *et al.*, 'Host genetic regulation of human gut microbial structural variation', *Nature*, vol. 625, no. 7996, pp. 813–821, Jan. 2024, doi: 10.1038/s41586-023-06893-w.

[43] S. R. Wiley *et al.*, 'Identification and characterization of a new member of the TNF family that induces apoptosis', *Immunity*, vol. 3, no. 6, pp. 673–682, Dec. 1995, doi: 10.1016/1074-7613(95)90057-8.

[44] K. Kakareko, A. Rydzewska-Rosołowska, E. Zbroch, and T. Hryszko, 'TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review', *J. Clin. Med.*, vol. 10, no. 6, p. 1252, Mar. 2021, doi: 10.3390/jcm10061252.

[45] S. K. Vasan *et al.*, 'ABO blood group and risk of cancer: A register-based cohort study of 1.6 million blood donors', *Cancer Epidemiol.*, vol. 44, pp. 40–43, Oct. 2016, doi: 10.1016/j.canep.2016.06.005.

[46] J. Höglund, T. Karlsson, T. Johansson, W. E. Ek, and Å. Johansson, 'Characterization of the human ABO genotypes and their association to common inflammatory and cardiovascular diseases in the UK Biobank', *Am. J. Hematol.*, vol. 96, no. 11, pp. 1350–1362, Nov. 2021, doi: 10.1002/ajh.26307.

[47] E. E. McGrath *et al.*, 'TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation', *J. Leukoc. Biol.*, vol. 90, no. 5, pp. 855–865, Nov. 2011, doi: 10.1189/jlb.0211062.

[48] S. Burgess, B. Woolf, A. M. Mason, M. Ala-Korpela, and D. Gill, 'Addressing the credibility crisis in Mendelian randomization', *BMC Med.*, vol. 22, no. 1, p. 374, Sep. 2024, doi: 10.1186/s12916-024-03607-5.

Figure 1. The causal relationship between LACTOSECAT pathway and TRAIL levels.

The **panel a)** shows the results of the main MR analysis between lactose and galactose degradation I pathway (LACTOSECAT PWY) and TRAIL protein. In the scatter plot, each dot is an IV and the x and y-axis represents the association coefficients with the exposure and outcome, respectively. The three lines represent the results of the three different MR tests, with the slope of the lines being equal to causal estimates of each test. The **panel b)** follows the same definition of panel a) but refers to results obtained using the GWAS data of the TRAIL protein from Folkersen et al., 2020 (GCST90012011) as outcome. In the **panel c)** the causal estimates from the leave-one-out analyses are shown and compared with the causal estimate from main analysis (red line). In the **panel d)** we show the post-hoc power estimates at varying causal effect sizes β_c, for different studies of TRAIL as outcome. The causal effect identified in the main analysis ($\beta_c = -0.19$) and corresponding power are highlighted in the curves.

(GWAS: genome-wide association study, IV: instrumental variable, LACTOSECAT PWY: lactose and galactose degradation I pathway, MR: Mendelian randomization, SNP: single nucleotide polymorphism, TRAIL: TNF-related apoptosis-inducing ligand levels)

EXPOSURE	OUTCOME	β_c	IVW post-FDR correction pval	WM pval	MR-PRESSO pval	Pleiotropy pval	Heterogeneity pval	Reverse causality pval	Replication
Coriobacteriales	AMD	0.61	0.047	0.007	0.009	0.44	0.75	0.98	NO
Coriobacteriaceae	AMD	0.61	0.047	0.007	0.009	0.44	0.75	0.98	NO
LACTOSECAT pathway	IL-15Rα	-0.2	0.03	0.038	0.006	0.32	0.20	0.64	NO
LACTOSECAT pathway	TRAIL	-0.19	0.006	0.009	0.003	0.66	0.52	0.997	YES
Bifidobacterium adolescentis	TNFSF12	-0.2	0.0003	0.0004	0.0004	0.61	0.83	0.84	NO

Table 1. Significant causal relationships between gut microbiome features and age-related traits.

This table shows the main results of the MR analysis. For each exposure-outcome pair, we show the causal estimate β_c, the p-value obtained with IVW method, after FDR multiple testing correction, and the p-value from all sensitivity analyses (weighted median, MR-PRESSO as pleiotropy aware MR-tests, tests of pleiotropy (Egger intercept) and heterogeneity (Cochran's Q), and the reverse causality). The last column indicates whether the causal relationship was successfully replicated using independent datasets.

(AMD: age-related macular degeneration, FDR: false discovery rate, IL-15Rα: Interleukin-15 receptor subunit alpha levels, IVW: inverse variance weighted, MR: Mendelian randomization, TNFSF12: tumor necrosis factor ligand superfamily member 12 levels, TRAIL: TNF-related apoptosis-inducing ligand levels, WM: weighted median)